Trial
NCT04445064
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators
—
Condition
Oropharynx Squamous Cell Carcinoma
Intervention
IO102
Why stopped
unmet primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-16